CARCINOMA, HEPATOCELLULAR
Clinical trials for CARCINOMA, HEPATOCELLULAR explained in plain language.
Never miss a new study
Get alerted when new CARCINOMA, HEPATOCELLULAR trials appear
Sign up with your email to follow new studies for CARCINOMA, HEPATOCELLULAR, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Second-line hope: regorafenib tested after lenvatinib failure in liver cancer
Disease control Not yet recruitingThis study tests whether the drug regorafenib can help people with advanced liver cancer whose disease got worse after treatment with lenvatinib. About 24 adults will receive regorafenib and be monitored for how long their cancer stays under control and for side effects. The goal…
Matched conditions: CARCINOMA, HEPATOCELLULAR
Phase: PHASE2 • Sponsor: Ju Hyun Shim • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New hope for liver cancer patients with liver damage: drug tested after immunotherapy fails
Disease control Not yet recruitingThis phase 2 trial tests the cancer pill regorafenib in 20 adults with advanced liver cancer and moderate liver dysfunction (Child-Pugh B) whose disease worsened after first-line immunotherapy. Participants take regorafenib daily for 3 weeks on, 1 week off, until the cancer progr…
Matched conditions: CARCINOMA, HEPATOCELLULAR
Phase: PHASE2 • Sponsor: Ju Hyun Shim • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New drug cocktail aims to stop liver cancer from coming back
Disease control Not yet recruitingThis study tests whether giving a combination of two drugs—lenvatinib and losartan—after surgery can lower the chance of liver cancer returning in patients whose tumors show 'tumor budding,' a sign of aggressive disease. The drugs work by breaking down collagen barriers around ca…
Matched conditions: CARCINOMA, HEPATOCELLULAR
Phase: PHASE4 • Sponsor: Second Affiliated Hospital of Xi'an Jiaotong University • Aim: Disease control
Last updated Jun 26, 2026 18:18 UTC